List of Personalized Medicine Companies in United States - 202

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

The 2bPrecise platform integrate genomic data withclinical knowledge and genomic research to identify relevant information for clinical care.

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

AbBC is a next generation ADC company that utilizes a biological conjugation process to target and deliver Granzyme B to cells for internalization and irreversible toxicity without the requirement of cleavage. Our pipeline of 7 fully human fusion proteins in ongoing preclinical development demonstrate inhibition and regression of tumor growth without toxicity. The platform enables the opportunity to methodically select ADC targets for development of new Granzyme B fusion proteins with major focus in oncology.

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

Access Genetics, LLC is a privately held Minnesota-based company founded in 2001 by Dr. Ronald McGlennen, an internationally recognized molecular diagnostics expert with over a decade of experience in implementing and developing molecular genetic laboratories. As a medical technology service company, we offer turnkey solutions to assist laboratories in the implementation of molecular genetic testing by recommending a tailored, cost-effective and state-of-the-art suite of hardware, software, prepackaged materials and supplies, process guides, custom tools, staff training, technical support, telemedicine interpretations, and other optional consultative services. This comprehensive service package makes Access Genetics unlike other companies in the genetic testing market that may only provide a piece of the testing puzzle. Our Mission is to improve the availability and utility of diagnostic genetic testing through a base of laboratory providers using our Web-Enabled DNA Testing Model. We partner with qualified clinical labs to enable them to build a quality in-house molecular genetics program that is simple, fast, economical and complete.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

Achira is building atomistic foundation simulation models to power the future of drug discovery.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

ActX, Inc. is a dynamic venture that is focused on making patient genomic information truly useful in everyday medical practice. We are currently seeking a Linux System Administrator/DevOps Specialist to work in a unique, small team environment where innovative new processes assist everyone's productivity. Join our team and help us make personalized medicine a reality rather than a dream!

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

At Amsterdam UMC, more than 15,000 professionals strive to provide good and accessible care. For the generations of today and tomorrow. The two medical university centers in Amsterdam, AMC and VUmc, are working together towards a future in which we prevent illnesses and make the best treatment available to all patients. To this end, we develop new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. We treat over 350,000 patients a year at both our sites - AMC and VUmc. Our main focus is on complex patient care and highly-specialized treatment of rare medical conditions. At Amsterdam UMC, we teach and train thousands of young people to become doctors, specialists or nurses. Our researchers are clustered in eight research centers so that we can achieve our ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching & training.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Anodyne is a venture-backed, clinical-stage biotech company focused on simplifying chronic care for all stakeholders. We specialize in the transdermal delivery of multi-milligram doses and complex formulations, enabling easier access to both existing therapies and emerging large molecule treatments. The HeroPatch, our proprietary technology represents a breakthrough in drug delivery. By transdermally delivering large molecules, it enables tunable pharmacokinetic profiles, new formulations using APIs in dry form, room temperature stability, and combination therapies of next-generation therapeutics. Our product pipeline is dedicated to addressing the unmet needs of chronic diseases, with an initial focus on obesity. We are committed to delivering innovative solutions that significantly impact patients' lives. Anodyne is actively expanding its pipeline through both internal clinical development and strategic external partnerships, maximizing the commercial potential and clinical impact of our advanced drug delivery platform.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

Aranscia unlocks the power of precision medicine by serving the needs of clinical professionals directly within the care workflow.

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

Harnessing the power of RNA biology to find treatments for patients with unmet medical needs. Advance and utilize the cutting edge antisense technology (siRNA and ASO) to discover and develop next generation medicines for both large and rare disease indications.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Aurita Corp is a synthetic biology startup that creates a platform for 3D bioscience intended to provide personalized medicine and diagnostics, therapeutic solutions, and cell culture tools.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

CELLINK is proud to be a part of BICO, the world's leading bioconvergence company. By releasing the first universal bioink in 2016, CELLINK democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. The company's best-in-class bioinks, bioprinters, software and services are trusted by the foremost academics in a range of applications, from 3D cell culturing to tissue engineering to drug development, and have been cited in over 700 publications. Furthermore, more than 1,000 laboratories, including ones at the top 20 pharmaceutical companies, are using these award-winning innovations. As part of BICO's bioconvergence revolution, CELLINK is dedicated to making the on-demand bioprinting of human organs and tissues a future reality and creating the future of health.

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

BioChain is the world leader in high quality processed bio-sample products and analysis services used in advancing translational medicine, companion diagnostics, and clinical product research and development. BioChain's products are available for DNA and RNA sequencing, PCR and RT-PCR, gene expression analysis, DNA and RNA purification, protein extraction and purification, protein expression analysis, and liquid biopsy studies. BioChain's One-Stop Services for Next Generation Sequencing (NGS), from clinical sample collection, sample preparation, sequencing to bioinformatics analysis, will revolutionize the industry. In addition to our world-class bio-specimen and sample preparation line of business, BioChain is moving into the clinical applications that offer clinical genomics diagnostics products and clinical trial services in cancer and reproductive health. BioChain is committed to achieving the Highest Quality products and services at highly competitive prices through our Continuous Process Improvement Initiatives. BioChain established a comprehensive quality assurance program to meet our customers' satisfactions as well as maintaining both ISO 9001:2016 and ISO 13485:2016 certifications for our in house production facilities. Innovation and Collaboration: As an industry leader, BioChain is always striving to innovate and collaborate with the world's leading Pharmaceutical, Bio Technology, and Health Care organizations. We have a strong in-house scientific team and actively seek research and business partnerships with industry innovators and leaders.

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

Formerly called Bioline, now acquired by Meridian Bioscience, as part of Meridian Life Science business unit, was founded in 1992 and based in London, UK. Meridian Bioscience is a fully integrated company with two business units dedicated to diagnostics and life science. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Meridian Life Science unit,with large-scale manufacturing capabilities and over 3500 products, provides the most comprehensive portfolio of raw materials for the clinical development of any immunological or molecular test. Our molecular reagents are used by biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology to food and agriculture technology as well as forensic and environmental sciences, where life scientists have come to depend upon the outstanding quality and reliability of our reagents. We have developed and manufactured a portfolio of more than 300 reagents and kits, many of them proprietary, for molecular biology, cell analysis and nucleic acid and protein separation and purification. Meridian operates under an ISO 13485 quality system and is one of the world's few manufacturers of ultra-pure dNTPs, as well as a variety of enzymes and biochemicals.

Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.

BioMarker Strategies has developed the proprietary SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients. SnapPath® is unique in automating and standardizing functional ex vivo profiling to capture the dynamic and predictive signaling information available only from live solid tumor cells. Our PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatments for solid tumors, because they are based on information available only from live cells. Our business development efforts are directed toward entering into funded collaborations with companies developing targeted therapies for patients with solid tumors. The capabilities of SnapPath® and the Functional Profiles it enables are available for Research Use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients.

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

BioSkryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry.

• The Cedars-Sinai Biomanufacturing Center (CBC) is a new 25,000 square feet, state-of-the-art biomanufacturing facility located in West Hollywood, California. • Manufacturing the next generation of cell and gene therapies for human IND-enabling clinical trials. • cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development laboratories. • Combined expertise in a cGMP-compliant approach to manufacture cells at scale with innovative technologies and equipment. • Transferring laboratory protocols to cGMP, up-scaling of processes and achieving Food and Drug Administration standards to bring innovative cell therapy solutions to researchers and translational scientists. • World-class expertise in stem cell (iPSC) biology, gene editing and bioprocessing. • Supporting California Institute for Regenerative Medicine (CIRMN) programs, CBC is providing a much-needed cell biomanufacturing center in California

CellNetix Pathology & Laboratories is a dynamic, rapidly growing private pathology company headquartered in Tukwila, WA, and serves hospitals and clients throughout the greater Puget Sound region. CellNetix provides comprehensive subspecialty clinical and anatomic pathology services, operates premier anatomic pathology laboratories, and offers complete pathology laboratory services at its central state-of-the-art anatomic pathology laboratory. CellNetix is known for pathologic excellence based upon pathologist subspecialization, for valuing intellectual capital at all levels of the company, and for delivering top-quality results. CellNetix is composed of more than 65 pathologists and 300 total employees. With our size, economies of scale, resources, and volume of referral material, we have created a centralized, state-of-the-art anatomic pathology laboratory leveraging best-in-class information technologies and equipment and lean process design. CellNetix has attracted highly talented professional, technical, and business leaders who provide each individual clinician and patient with focused, personal service. CellNetix believes that local pathologists partnering with local clinicians and hospitals results in the best possible patient care. We use the extensive expertise of our pathologists and laboratory personnel to bring that level of care to each and every patient.

At Cerba Research we provide world-class clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of healthcare by transforming research and advancing health together. We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & and spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation of human-centric healthcare, by transforming research, and advancing health together. Uniquely, we combine the experience of specialty laboratories with the global reach of a central lab. We have a worldwide network of 1000 labs, hold data from over 85 million patients across five continents, and have the ability to sequence 1000-plus whole human genomes per week. This unparalleled approach to patient data gives you the opportunity to have one partner for all your test services, with consistent access and support across all clinical trial phases.

CeutiCare improves outcomes and lowers medical costs of treating the chronically ill patient. CeutiCare's Intelligent Clinical Guidance (ICG) system provides knowledge-based technology to support evaluation of patients by a pharmacist or other physician extender at the patient's point of care. Our proprietary ICG system evaluates patient clinical data and recommends patient-specific, evidence-based medication therapy to help the patient get better and feel well.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

CHCFbrain.org is a non-profit organization and advocacy group, centered around neuro-development with focus on long-term solutions. The long-term goals, which are the focus of CHCF , are to promote research to 1) identify the root cause(s) of serious learning disabilities and neuro-developmental delays and disorders with mental health manifestations; 2) develop objective unbiased "blood based" diagnostics; 3) develop curative therapies based on these not yet identified or characterized genetic and epigenetic markers. Hypothesis: A common set of gene(s) are involved in diseases of brain including Alzheimer's, Parkinson's, Autism, learning disabilities & neurodevelopmental delays and serious mental health conditions. Mission Statement: To accelerate research in biomarkers for early diagnosis of high risk conditions that affect brain function and to develop novel targeted curative therapies based on molecular causes of these conditions discovered through epigenetic and genetic research. To provide parents and health care professionals objective tools to support development of children very early on as infants and toddlers based on objective behavioral and psychological assessments. We are born with inherent characteristics that define our personality and who we are. Some of us learn to thrive and some of us struggle to master and learn how to cope with our environment. For the majority of us this is not because we have mental health conditions but it is because we are not equipped to thrive in the environment we live in. We at CHCF believe that each person is very unique. We also believe that in order for our children to thrive emotionally we must have objective diagnostic tools that could identify 1) the optimal thriving environment for each child early on and; 2) how each child can learn critical skill sets to cope with inevitable adverse events in the existing global environment. To do so this requires a new approach in understanding who we are. Please join us!

Sutter Health is one of the nation's leading not-for-profit healthcare systems, which includes award-winning physician organizations, acute care hospitals, surgery centers, medical research facilities and specialty services. Our team of 68,000 doctors, employees and volunteers proudly cares for Northern California. Our facilities and care centers are located in large, urban cities and small, rural communities, from the Pacific Coast to the San Joaquin Valley. You'll find us in San Francisco, Oakland, Sacramento, the snowy mountains of the Sierra Nevada and Lake Tahoe, Napa Valley, Yosemite and the coastal redwoods. We even have an affiliate in Hawaii. Join us and be part of a dedicated group of professionals committed to putting patients' needs first and achieving the highest levels of quality, access and affordability.

Culmination is changing the world by discovering better health. We provide unparalleled value to health care organizations by unlocking biological data and enriching it with clinical, claims, and genomic data. We are on a journey to radically improve everyone's future health care experience. Culmination Bio will become the trusted source for health care insights and for generating discoveries that improve people’s lives.

Cureline is a global precision and translational medicine CRO located in California (USA). With more than a hundred validated clinical partners in 20 countries, HBS repository in San Francisco Bay area and excellence in laboratory services, Cureline provides a full spectrum of translational research services: global regulatory affairs, custom protocol HBS biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2003 Cureline is a global leader in commercial biobanking and biomedical research services with a focus on targeted drug R&D, biomarker research and companion diagnostics development.

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

DLS is proud to be Hawaii's largest locally-owned clinical testing laboratory with a team of 800+ dedicated professionals. Our Microbiology Lab is the only clinical laboratory in Hawai'i with the WASPLab, a highly advanced specimen processor. Our Core Lab features a chemistry automation line that is the largest of its kind in the state. It also utilizes mobile robots that efficiently deliver samples between processing stations. We know that when it comes to the wide variety of lab tests we perform, quick, accurate results and analyses improve health and save lives. At DLS, we are committed to excellence in laboratory science and stand by our guiding values, I.C.A.R.E.: I - Innovation C - Care A - Aloha R - Respect E - Excellence We work closely and collaboratively with physicians, medical groups, hospitals and clinics. Our employees are what makes DLS a successful company and we strive to provide an environment of growth and professional development for our versatile and high-performing workforce. Beyond lab results, we build relationships and create collaborative partnerships with the communities we serve. No matter what your position is at DLS—medical technologist, medical laboratory technician, technical laboratory assistant, phlebotomist, systems engineer or patient account representative—your role will impact patient health. When it comes to living in Hawai‘i, we at DLS are committed to making our newest members feel at home with guidance and support. We believe in a healthy work-life balance, and we want our team members to take full advantage of our islands' natural beauty and great year-round weather.

A unique laboratory providing accurate and actionable results in one day for infectious diseases and antibiotic resistance genes utilizing innovative molecular technologies, including proprietary TEM-PCR™. Eurofins Diatherix distinctions: - Delivers one-day results - Identifies bacteria regardless of recent antibiotic use - Offers simplicity of single-sample collection - Identifies difficult-to-culture pathogens - Yields a high level of sensitivity and specificity

DNA Software is the preferred partner to solve your diagnostic design and analysis problems.Our customized software platform predicts the “sweet spots” in the target and designs with optimum sensitivity and specificity. DNA Software provides diagnostic solutions to our partners saving time, money and resources, including difficult multiplex panel design for the most challenging targets.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

As a nonprofit engineering innovation company, Draper serves our nation's interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers' needs and to deliver new capabilities to them.

Duality's breakthrough innovative technologies eliminate the conflict between data protection and business growth and innovation. The Duality Data Analytics and AI platform is built upon advanced encryption methods, hardware technologies, and machine learning techniques that protect sensitive data while in use. Duality is the only multi-PET platform with the ability to combine various technologies to meet the unique needs of sensitive data operations. These guardrails streamline and enhance the data operations critical for data-driven insights and innovations by eliminating bulky, expensive, and limiting processes like data anonymization and tokenization. Traditional data protection methods prevent organizations from truly adopting and leveraging advanced models to their benefit, resulting in restrictive policies like "no sensitive data can be used for model training." With Duality, organizations can confidently customize 3rd party models on their own data without fear of data leaks. Model providers can scale model customization knowing that their proprietary model is never exposed to the customer, preventing competitive intelligence leaks. Financial institutions can turn their manual KYC requests into self-service operations, greatly enhancing the speed and success of these expensive requirements. The benefits of data protection guardrails span from efficiency gains, to unlocking previously inaccessible data, to slashing costs on high-security infrastructure.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product is the TLPO vaccine, an autologous therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient’s specific cancer. Therapeutic cancer vaccines are an attractive immunotherapy because of their potential safety, specificity, and long-lasting response due to stimulation of immune memory.

Elucida Oncology is a biotechnology company that pioneers targeted cancer therapy with ultra-small nanoparticle C’Dot drug conjugates designed to penetrate deep into tumors.

Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform powers the Lupus Landmark Study, the largest clinical study for lupus in the world, the Human Epilepsy Projects and tens of other clinical studies for pharmaceutical companies, biotechs and patient groups. More than half of the top 10 Investigational sites in the US use our platform: John Hopkins, NYU, UCSF, Yale, UPenn, Washington University in St Louis, Cornell and many others also such as Mayo Clinic, Yale, Georgetown.

Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers potentially unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders.

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exceltox is a CAP-accredited, CLIA-certified laboratory offering advanced clinical, pharmacogenomic,and toxicology testing.

Fore Biotherapeutics - We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.

GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou's laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings ("LabCorp") and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric's second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.

Genemarkers is a Kalamazoo, Michigan-based contract services laboratory specializing in genomics research and molecular testing services, with a primary focus on consumer products, dermatology, skin-related research and therapeutics.. Founded in 2008 by former professor and neuroscientist Dr. Anna Langerveld, Genemarkers has proven its expertise through collaborations with cosmetic, pharmaceutical, and academic research institutions over the years. Taking pride in providing actionable, high quality data and customer service, Genemarkers' CLIA-certified and CAP-accredited laboratory has the ability to support a wide range of projects throughout discovery and development including advanced cellular models/exposures (e.g., dermal/transdermal, hepatic/extrahepatic, neuronal and bronchial/inhalation) and next generation bioinformatics and computational modeling.

Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease.

Geneticure optimizes prescription drug therapy by using patients’ DNA to guide their blood pressure treatment with a new, actionable tool, supported by clinical evidence to help you provide even better care for your hypertension patients.

GENETWORx Laboratories was formed with the central focus of impacting the lives of our people by empowering their physicians with information. Now, GENETWORx is dedicating our focus to fighting back against COVID-19. GENETWORx' COVID-19 test is the gold standard due to being 10% accurate, with 10% sensitivity and specificity. GENETWORx's COVID-19 test detects infection in the earliest stage, with a long turnaround time. Once a sample has been received in our laboratory, the prescribing physician will have the result via GENETWORx's portal within 10 business days. GENETWORx provides ongoing COVID-19 testing so that states, employers and organizations can continue or again open their operations with a safe and healthy workforce. We are completing thousands upon thousands of tests a day, and are growing to ensure that everyone in the USA can be tested and return to work. GENETWORx has met the Federal and State licensure requirements to operate in all 50 states. • CAP Number: 8732425 • CLIA Number: 49D2060159 Learn more about COVID-19 Testing: https://www.genetworx.com/faqs Our core values: • Personalized patient-centric care • Translating science into actionable intelligence • Supporting doctors and pharmacists in their delivery of top-quality Personalized Medicine • Enabling cost-effective health care • Preserving patient privacy

GENEWIZ from Azenta Life Sciences Company, is a leading global genomics service provider serving thousands of researchers in institutions worldwide. GENEWIZ offers a suite of solutions including DNA synthesis, sanger sequencing and next generation sequencing to accelerate antibody discovery and development research. Other services also include bioinformatics, GLP regulatory, and clinical services. From the company’s founding, GENEWIZ has maintained an unwavering commitment to providing customers with the best combination of quality, service, and value. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. At GENEWIZ, it is our mission to contribute to the advancement of life sciences and technologies. Together with our clients, we can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Our goal is to be the best in the world and the best for the world. Headquartered in Leipzig, Germany and South Plainfield, NJ, GENEWIZ has additional locations in Takeley, United Kingdom; Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; Seattle, WA, Beijing, China; Suzhou, China; and Tokyo, Japan.

A premier research institution providing global genomic profiling and molecular diagnostics services to academic centers, pharmaceutical and biotech industry, oncologists, and pathologists with innovative diagnostic, prognostic, predictive, and personalized testing. Genome Explorations, a Tesis Biosciences company, is a state of the art CLIA certified GLP compliant Lab providing NextGen sequencing, Genotyping, Gene Expression and microRNA profiling services. Our Clients range from Fortune 500 Pharmaceutical and Biotech to Individual Investigators at Academic institutes and are located worldwide. Our experienced scientists work one-on-one with researchers and clinicians to provide a ‘Complete Solution' for all their Research and Clinical needs, from experimental design to in-depth data analysis and advanced bioinformatics. Genome Explorations also offers ‘Complete Solutions' for challenging specimens, such as whole blood and FFPE tissues.

Our mission is to enable a world where everyone's health is informed by genetics. As a leading telegenetics care delivery company, we make genetics care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. We partner with health systems, genetic testing laboratories and biopharmaceutical companies. We accelerate, grow and provide service to their patients by launching genetics programs from the ground up, improving the scale and efficiency of existing genomic medicine programs, and providing genetic expertise and services to support clinical trials and sponsored genetic testing programs. With the largest national network of telehealth genetic counselors – averaging 10 years clinical experience – We have delivered more than 200,000 genetic counseling encounters, scaling to more than 8,500 patients per month and helping health systems expand network reach to more patients by delivering genetic care to patients anywhere, seven days a week. We are a covered benefit for 130 million people in the U.S. Through our nationwide virtual care delivery model, we provide genetics care to patients when and where it is most convenient, reducing patient wait times from as much as 18 months to one week. We have an extensive team of clinicians, including medical geneticists, genetic counselors, physicians and pharmacists. Our clinical specialties include oncology, reproductive health, cardiology, pediatrics, rare disease and proactive health.

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

Genosera is revolutionizing the gene therapy field with its next generation gene therapy treatments that can help stop the progression of diseases and allow patients to regain their health. Founded in 2019, Genosera is a privately held, gene therapy biotechnology company located in Columbus, Ohio.

At Genospace, our mission is to deliver the platform that makes biomedical data useful and usable by everyone. Genospace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by Genospace. Please visit www.genospace.com for more information.

GNS Healthcare is a healthcare analytics company that specializes in precision medicine and biomedical research through advanced health data analysis.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Molecular Diagnostics

Heligenics is a life sciences company that has developed proprietary technology, which shows the impact of genetic mutations to revolutionize genetic testing and drug development for major diseases. We are the first company to develop High Content Screening for Biologic Drugs, previously the mainstay for the development of small compound drugs. As the effect of most mutations on gene function is largely unknown, Heligenics comprehensively measures the functional significance of mutations in the human genome through a massively parallel in-vitro process called the GigaAssay, measuring the impact of all potential amino acid substitutions in the functional target protein, doing in a few months what would take many years to do if at all. For cancer diagnostics companies, our functional data enables improved genetic test interpretation, and for pharmaceutical companies, we empower the conversion of generic drugs into targeted precision medicines or can rescue a failed drug candidate through the identification of variants for a redesigned genetically stratified clinical trial. Explore more! Email: mschiller@heligenics.com Website: Heligenics.com LinkedIn: linkedin.com/company/heligenics-inc/ Twitter: twitter.com/heligenics

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Rapid Syndromic Testing for All Labs The mission of iCubate® is to provide rapid, accurate and affordable syndromic testing to all laboratories to ensure care providers have the right tools to improve care and outcomes for their patients. The iCubate® team has developed the iC System™, a low-cost, fully automated, molecular diagnostic platform using armPCR technology, along with a suite of syndromic infectious diseases panels, including sepsis/positive blood cultures, upper / lower respiratory tract infections, GI, mycobacteria, and more. Why iCubate for your lab? • Rapid syndromic testing for infectious diseases for better care, sooner • Affordable system increasing accessibility for large and small labs • Multiplex assay with high target specificity and sensitivity for actionable results • 3 minutes of hands-on time with routine lab processes Twitter: @iCubate FDA Cleared Products iC-System™ (iCubate’s platform) iC-GPC Assay™ for Gram positive cocci Anticipated clearance 2019 iC-GN Assay™ for Gram negative rods Robust Assay Pipeline GI, Respiratory, Mycobacterium

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s lead program is IDRX-42, designed to inhibit key genetic drivers and drug-resistant mutations of KIT in gastrointestinal stromal tumor (GIST). IDRx's pipeline also includes a second KIT inhibitor, IDRX-73. Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development, and commercialization of more than 10 approved drugs. To learn more, please visit www.idrx.com.

immunArray is a molecular diagnostics company that is engaged in developing novel blood-based tests to support the diagnosis and management of autoimmune diseases.

ImmunoMind is a UC Berkeley SkyDeck alumnus company, focused on understanding drug-human interactions to create more effective immunotherapies for underserved populations.

Enabling Nucleic Acid-Based Medicines to Treat Solid Tumor Cancers Ground-breaking Impilo Platform™ The Impilo Platform™ is designed to address key issues that have limited ability of emerging nucleic acid-based therapeutic modalities such as antisense, siRNA, tRNA, and mRNA and in vivo gene editing to effectively treat solid tumor cancers.

INCELL manufacturesand develops effective treatments for unmet medical needs.

Inductive Bio is a biotechnology company based in San Francisco, California, founded in 2022. The company specializes in using advanced machine learning and data analytics to enhance the compound optimization process in small molecule drug discovery. With a seed funding of $4.3 million, Inductive Bio aims to address challenges in Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) during drug development. The company's core offering is a proprietary dataset combined with sophisticated machine learning models. This platform enables scientists to efficiently optimize initial compounds into viable leads and development candidates, providing real-time predictions and insights throughout the drug design process. Inductive Bio collaborates with pharmaceutical companies, biotech firms, and research institutions, including a partnership with Nested Therapeutics focused on precision medicine for challenging cancers.

Inform Diagnostics, a Fulgent Genetics Company, is a leading pathology laboratory trusted by clinicians throughout the U.S. We provide timely, accurate and definitive patient diagnoses in the fields of dermatopathology, gastrointestinal pathology, hematopathology, neuropathology, breast pathology, molecular diagnostics (Covid-19 testing), and genitourinary pathology. Working for Inform Diagnostics means you will contribute alongside top multidisciplinary talent in an environment with cutting-edge tools and breakthrough technologies. It is a place where people are passionate in their belief that every patient deserves the right answer. Driven by an unwavering dedication to quality, Inform Diagnostics profoundly impacts patient care, one diagnosis at a time. The company has state-of-the-art laboratories in Boston, Dallas, New York City, and Phoenix. Visit us at informdx.com.  

The OcuCheck is a point-of-care device that uses a specialized electrical chemical sensor with proprietary coatings to measure specific biomarkers in the tear film Currently, the OcuCheck is the only device that can simultaneously measure MMP-9 and tear film osmolarity in one device. It is also one of the most accurate devices for quantitative measurement of MMP-9.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

InsightRX empowers life science and provider healthcare organizations to individualize treatment from clinical development to the point of care.

Interpace Biosciences develops molecular diagnostic tests under the brand Interpace Diagnostics, and provides clincal trial services under the brand Interpace PharaSolutions.

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging human-identical molecules as new medicines. Their initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells as well as the gut microbiome

ioGenetics

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings

The Iowa Institute of Human Genetics (IIHG) is dedicated to promoting clinical care, research and education focused on the medical and scientific significance of variation in the human genome. The IIHG serves as a statewide resource for outreach about issues related to understanding the extent and meaning of human DNA sequence variation.The Institute is within theRoy J. and Lucille A. Carver College of Medicine, a highly ranked medical school where students learn to become accomplished clinicians and top-flight researchers and educators. Students come to Iowa to study medicine in a program that uses case-based learning as the basis of their education.The College is part of University of Iowa Health Care—a fully integrated academic medical center, which also includes the University of Iowa Hospitals & Clinics, and University of Iowa Physicians, the largest multi-specialty group practice in Iowa. As the state’s only comprehensive academic medical center, UI Health Care is committed to world-class patient care, biomedical research, and medical education.

Ipsum Diagnostics is a nationally acclaimed molecular diagnostics laboratory, renowned for its expertise in identifying infectious disease pathogens and antibiotic resistance genes. Our molecular panels leverage the power of polymerase chain reaction (PCR) technology and provide fast results for more effective treatment that leads to improved patient outcomes. Located in Atlanta, GA, our state-of-the-art laboratory specializes in molecular and anatomical pathology. We accommodate workflow needs by providing services such as customized reports, statistical analysis of patients with different treatment plans, and meaningful data to assess overall treatment performance amongst patient populations. Our comprehensive and succinct patient reports can be made available via EMR integration, portal access, fax, or our easy to use mobile or tablet app. Ipsum's software capabilities allow for a superior customized experience, with the highest quality standards that will have your reports completed promptly and efficiently. Ipsum Diagnostics creates a true partnership environment between Provider, Patient, and Laboratory. For locations needing a UPS pickup please follow the below instructions: 1. Call (800) PICKUPS 2. When prompted reply "Schedule a pick"​ 3. You will be asked for your phone number 4. Be prepared to have tracking number ready to provide 5. Provide address of pick up with a time frame UPS Phone Center Shortcuts: https://www.ups.com/us/en/contact/ivr-Popup.page?

iXpressGenes is a synthetic biology company thatspecializes in protein services and instrumentation, and protein and genetic engineering research. The company has experience withextremozymes, microgravity, and trace fluorescent labeling andaccess to a suite of hyperthermophilic genomes from the deep sea vents of the Atlantic Ridge. Proteins and enzymes from these genomes have special qualities that are useful in engineering and metabolic reactions.

JBS Science is a biotechnology company that specializes in developing circulating cell-free DNA (cfDNA) in urine technology for improved cancer screening and management through liquid biopsy.

Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve.

At Kite, a Gilead Company, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many people with cancer as possible who may benefit. Cancer is personal to us. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about changing the future of cancer treatment, let’s talk.

Proprietary applications in diagnostics and therapeutics. International technology development. Translational medicine impacting Immunology, Oncology and Genomics.

Lab Genomics, LLC (LG) is focused on delivering individualized medical care through molecular and genetic diagnostics.

LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending. Based upon our scientists' discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes. The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.

Leveragen is a Boston-based biotech company specializing in genetic engineering. We develop comprehensive solutions for genetic modeling, creating designer mutations to study gene function and disease mechanisms. Currently, we are focused on engineering next-generation genetic models to enable the discovery of diverse biologic modalities, facilitating the development of novel diagnostics and therapeutics.

LifeNome's AI algorithm looks at 9000+ genetic variations holistically (rather than other companies that look at single gene associations)to assess your overall predispositions for nutrition, fitness, skin care and many more wellness traits.​

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

PCI is your world leading CDMO, providing integrated end-to-end drug development, manufacturing, and packaging solutions to increase product speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. With 30 sites across Australia, Canada, North America, the UK, and Europe and over 6000+ dedicated employees, together, delivering life changing therapies. Leading technology and continued investment enable us to deliver development to commercialization solutions throughout the product lifecycle, collaborating with our clients to improve the lives of patients globally.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine.

MantleBio is building software to scale data driven discovery in biotech. It has become the norm for biotech companies to generate terabytes of data per day, but the majority of them lack the tools effectively utilize it. Through data management and analysis tools MantleBio provides an infrastructure for companies to make data driven decisions.

The mission of the Medical College of Wisconsin is to be a national leader in the education and development of the next generation of physicians and scientists; to discover and translate new knowledge in the biomedical sciences; to provide cutting-edge, interdisciplinary and compassionate clinical care of the highest quality; to improve the health of the communities we serve. Founded in 1893 as the Wisconsin College of Physicians and Surgeons. Formerly associated with Marquette University.

Patient populations and their medications are continuously moving. MedTek21 ensures your entire patient base is continuously monitored for potential drug/gene interaction risks, allowing you to focus your care.

Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.

Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to accelerate the next generation of precision medicines for immune-mediated diseases.

MiraDX was founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to improve personalized cancer treatment. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do. Through worldwide collaborations MiraDX has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDX.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.

MutantDxidentifies DNA mutations in blood thatdiagnose cancer early enough to bepotentially curable.

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

Nashville Biosciences is leveragingresources and proprietary analytical methods to help improve the prevention, diagnosis and treatment of a wide range of diseases.

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients. We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.

Nexus Dx is a global provider of Near Patient Testing systems and advanced diagnostic solutions. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. Company Highlights: Primary focus on expansion of assay systems in the Near Patient Testing industry Multi-product revenue generating business Proprietary technologies and content Highly experienced management team Nexus Dx Inc.

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways.

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

NVIGEN is a nanobiotechnology company that specializes in multifunctional nanoparticles for biomedical applications through their proprietary NID platform.

NX PharmaGen develops blood-based molecular diagnostic testing products.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Developing metabolomics assays and machine learning algorithms to produce “Biomarkers of Response” (BoR) that differentiate drug responders (R) from non-responders (NR).

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: Agkura™ Personal Score – a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. Agkura™ Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.

Discover the benefits of Nucleic Acid Programmable Protein Arrays(NAPPA). The Ordinatrix team includes co-founders Prof. Josh LaBaer and Prof. Ji Qiu from Arizona State University, joined with biotech/life science executive Jim Hauert. Our goal is to be the leader in translational proteomics through the creation of the most functional, flexible, and precise protein microarrays in the industry based on our attention to quality, intellectual property, and many years of experience with the Nucleic Acid Programmable Protein Arrays (NAPPA) technology, which will aid in the development of new drugs, diagnosis of disease and approaches to personalized medicine.

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

PCI is your world leading CDMO, providing integrated end-to-end drug development, manufacturing, and packaging solutions to increase product speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. With 30 sites across Australia, Canada, North America, the UK, and Europe and over 6000+ dedicated employees, together, delivering life changing therapies. Leading technology and continued investment enable us to deliver development to commercialization solutions throughout the product lifecycle, collaborating with our clients to improve the lives of patients globally.

Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer. Notice to recruiters All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees. In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department.  Notice to Recruiters; Peak Bio’s receipt or acceptance of an unsolicited resume submitted by vendor organization does not constitute an actual or implied contract between Peak Bio and such organization. Peak Bio will not pay a fee to any vendor that does not have such agreement in place.

Phenome Health is a research organization dedicated to preventing disease and taking the guesswork out of healthcare. We are driving a revolution by moving past the disease-focused “find it and fix it” era to wellness and prevention that enables all of us to live longer and healthier lives.

We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patient's health, while also reducing adverse reactions. Our PrecīsMed platform represents a significant step forward in accurately assessing a patient’s complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PrecīsMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.

PhotonPharma is an immuno-oncology company with a break-through technology that stimulates a patient's own immune system to seek out and destroy their cancer cells. We have a patent protected process that precisely inactivates DNA/RNA of a patient's own tumor cells while leaving the cells alive with all of unique tumor specific antigen targets (neoantigens) intact. The process is simple, fast and inexpensive. A patient's tumor cells can be extracted, inactivated and administered back on the same day. Efficacy and safety has been demonstrated in a dog trial (companion animals) and in mouse studies.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders. We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain.

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

Prenosis, decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes

ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever. With AAGP, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve. ProtoKinetix has harnessed a molecule found in nature with the power to transform lives and the future of health care. Founded in 2002, ProtoKinetix secured a patent for anti-aging glycopeptide (AAGP), a naturally-occurring molecule that regenerates cells for animals surviving in arctic temperatures. AAGP has gone through a series of tests in laboratories throughout Europe and North America conducted by some of the best researchers in the world. Backed by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable and effective in protecting and regenerating cells. This molecule could be the link to improved treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease and so much more. There is endless potential, and we’ve only seen the tip of the iceberg. Become part of the next great medical discovery.

Psomagen, Inc., formerly Macrogen Corp, delivers genomic sequencing services to the clinical, academic, and consumer markets. Psomagen's labs are US-based and CLIA and CAP certified. Not only is the company accredited to perform the highest quality Sanger sequencing, Next-Generation Sequencing and Microarray Gene Analysis, it is also networked with Macrogen's worldwide headquarters, stretching its capabilities and capacity across a diverse set of labs around the world. Learn more at psomagen.com.

Q uses a systems biology approach called panomics to build a comprehensive, quantitative snapshot of your health by combining advanced non-invasive imaging, chemistry, genetics, vitals and your medical history.

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

QuickBiology is a fully automated, high-throughput genomic center equipped with all major next generation sequencing. QB provides state-of-the-art genomics technologies, comprehensive services, specialized expertise enabling these services in a cost-effective and timely manner to serve basic science and translational/clinical research. QB’s service included, but not limited to, RNA sequencing, whole exome sequencing, whole genome sequencing, ATAC sequencing and single cell RNA sequencing.

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

The last decade has seen amazing progress in neuroscience, enabling researchers to envision a new generation of brain machine interfaces. These systems will be used to treat chronic diseases like Parkinson's, epilepsy, and Alzheimer's. They will restore mobility to the paralyzed and speed recovery from a stroke. They may even allow us to control our mood and enhance our cognition. Rune Labs wants to build the software at the heart of these systems, and help accelerate the next wave of neuromodulation applications.

Santa Ana Bio is a precision immunology company leveraging multi-omics platforms and antibody engineering to deliver targeted therapies to patients with autoimmune and inflammatory diseases.

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and fully-integrated discovery capabilities leveraging the most advanced technologies across cancer biology, medicinal chemistry and data sciences. Our current pipeline, led by our mutant-selective PI3Ka program STX-478, consists of three internally discovered clinical product candidates in addition to multiple discovery-stage programs. Our focus is on solving current gaps in therapeutic options for patients with cancer by discovering and developing exquisitely-selective product candidates against well-validated, previously undruggable targets to improve patient outcomes.

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline. Sengenics is headquartered in the U.S. and has a worldwide network of offices, distributors, and service providers.

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

Free, unlimited storage with analytic tools to save you time. DNA app market place.

A pioneering, proven approach to antibody discovery that delivers actionable leads by capturing all available data.

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohn's, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still aren't real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000's different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.

Sword Bio is a bioanalytical CRO committed to delivering projects with the best-in-class quality, science, service, and speed. We are a team of experts in the bioanalytical CRO field, bringing over 30 years of experience to your project. We specialize in developing, qualifying and validating PK, Biomarkers and immunogenicity assays. At Sword Bio, we have the flexibility to respond to your evolving needs, from assay development to clinical testing in an Non-GLP or GLP environment. We will work with you to maximize your resources and begin your projects immediately, priding ourselves on timely results and open communication. Sword Bio offers a rapid, customized, collaborative and an accessible new way of working with a CRO. Sword’s mission is the same as yours: to quickly and reliably bring essential drugs to those who need them.

SimBioSys is a pioneering TechBio company leveraging artificial intelligence and biophysical modeling to harness the power of spatial biophysics to redefine precision medicine, transform patient care and defeat cancer. By seeing cancer more completely, SimBioSys aims to empower clinicians and researchers with a more informed understanding of a patient’s tumor to optimally assess all available options and deliver on the promise of truly individualized patient care. To learn more, visit us at https://www.simbiosys.com/.

SYTE.bio is a Synthetic Biology Start-Up company developing precision DNA & RNA-based therapeutics and vaccines. The company has been incorporated as a Delaware C Corp in 2021 (SYTE.bio, Inc), and has labs & offices in Argentina's headquarter, that has been operating since 2017. SYTE.bio is pioneering the development of life-changing treatments for severe diseases and vaccines to treat and prevent diseases at the molecular and cellular level using engineered DNA, improving life through innovation. SYTE.bio’s powerful redosable DNA & RNA delivery platforms will unleash the potential of personalized genetic medicine in multiple potential applications, such as Gene Therapy (Oncology, Monogenic Diseases, Cardiovascular Diseases, Vaccines, Orphan Diseases), Cell Therapy (CAR-T Therapy, Induced Pluripotent Stem Cells (iPSC)) and Gene Editing (CRISPR/Cas, TALEN, ZFN).

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity's greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio's technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

The Northeast Biomanufacturing Center and Collaborative (NBC2) is a National Science Foundation Advanced Technology Educationregional center that has been in existence since 2005. It's mission is tocoordinate local and regional efforts into a national biomanufacturing education and training system to promote, create, and sustain a qualified workforce with a vision to be the nationally recognized center of excellence that develops a world-class sustainable biomanufacturing workforce to improve the quality of life.

Trace Biosciences is creating imaging agents for surgery. Our mission is to revolutionize surgery by highlighting detailed anatomy in real-time. Our first product is a nerve targeting imaging agent that will prevent surgical nerve damage. Nerve injury is a feared surgical complication affecting 25 million patients annually and incurring undue pain, loss of function, and high cost for follow on treatment and pain management. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. If we can successfully develop this, our imaging agents will be used in almost all operating theaters, enable true precision surgery, and vastly improve patient outcomes. We are well funded through non-dilutive grants (SBIR, STTR + regional government) as well as venture capital investments. Founded in 2019 we are now developing our first products that will enter clinical trials in 2023.

Tradewind is dedicated to creating therapeutics for the most aggressive, difficult to treat cancers. Our lead program is a high-affinity, multifaceted attack antibody for cancer that functions through the inhibition of a novel, but validated, target protein. Tradewind’s first-in-class lead program operates through multiple modes of action - directly on cancer cells, and through the immune system, with both mechanisms of attack substantiated by in vivo studies. We can target the primary cancer, metastatic tumors, and even stop metastasis from spreading further. Our mission is to develop only transformative medicines that will have a significant impact on patient outcomes. Tradewind’s drug development is paired with a focus on biomarker identification, ensuring that our therapeutics will benefit the patients for whom it is most meaningful. The lead program is expected to be a game-changer for ovarian cancer, followed by other indications. Tradewind is backed by Y Combinator and the National Cancer Institute (NCI) to advance its innovative approach to fighting cancer.

Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact.

Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits. They’re using cutting-edge sequencing technology, statistical genetics, and machine learning to identify entirely new therapeutic targets.

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine — a continuous flow of knowledge between researchers, scientists, and clinicians around the world, fueling innovation and creating insights that radically improve human health. Our goal is to use data to radically improve healthcare globally and create value through multiomics and insights. If you’re interested in learning more about Velsera, please follow us and visit our website at velsera.com! Looking for someone to get in touch with? Please email hello@velsera.com

Verséa, is a US-based healthcare company is comprised of 4 divisions: Verséa Therapeutics, Verséa Diagnostics, Verséa Scientific Discovery & Verséa Ophthalmics. Regardless of which vertical within Verséa, our committed medical and executive team focus on transformative health solutions for patients, caregivers and healthcare professionals, delivered with care. With a combined 500+ years of expertise, the Verséa team has achieved both national and worldwide success in highly regulated markets. The Verséa team consists of experienced multidisciplinary business executives and prominent scientific medical experts in their respective fields of specialties, who collaborate to provide solutions to healthcare challenges humanity is facing today. To find out more, visit our corporate website: www.verséa.com

By informing veterinarians and pet parents about which mutations are causing their pet's cancer to grow and spread, we intend to open up the use of precision medicine to combat canine cancer in new and more effective ways. Vidium is dedicated to unravelling the genetic components of common and complex diseases, including cancer. As a result, the practice of medicine targeting these conditions can be more rational, more precise and more personal. Our focus is on shifting paradigms in cancer treatment to enable cures for cancer and other serious diseases in pets through programs at the intersection of personalized medicine and comparative genomics.

Simplifying Cancer's Complexities. With the complexities of cancer care exploding due to the paradigm shift towards precision medicine, we saw a need for a platform that actively assists clinicians. We call this Halo Intelligence. Halo Intelligence is the first whole knowledge system that brings together everything clinicians need to find the right treatment plan for every patient, every time. It does this by distilling data from all aspects of the VieCure EcoSystem. The end result is a seamless marriage of artificial intelligence and the clinicians' own natural intelligence creating what we call, The Halo Effect. https://www.viecure.com/careers

VITRUVIAN BioMedical, Inc is a biotechnology company focused on a unique Business Strategy based on Early, Medium and Late Stage product development. We are committed to providing "Advance Personalized Medicine" to medical professionals and patients globally". Our strategy increases the goal of success and is implemented with key partners in the biotech and pharmaceutical industries. Our current focuse is on Alzheimer's Disease (AD) utilizing a breakthrough Therapeutic Vaccine which targets ABeta and TAU and an AD Biomarker for early stage detection.

Our mission is to provide you with answers that can't otherwise be found because this information is unique to only YOU! Knowledge equals the power to work smarter and not harder; this is a key factor to achieving optimal results in any aspect of life but here at MelixGX™ it is particularly relevant to one's success in accomplishing the highest level of health, fitness, and overall well-being that many of us strive for. MelixGX™ was initially intended to focus on the fitness aspect of health and the countless number of contributing factors. These factors include the necessities (exercise regimen, diet, supplements & more) specific to every individual's body type that enable s/he to achieve their goals; our final product MelixFit™. Following this extensive research, we discovered the most common battles millions of Americans face each day, this inspired us to explore the many benefits of Cannabis. The correct strain (again, specific to one's DNA) has inimitable capabilities that include but are not limited to aiding in physical recovery, effectively and efficiently battling chronic pain, anxiety, depression, addiction, insomnia and so much more. Our final product MelixMJ™. Through sophisticated advances in technology, our knowledgeable and skilled geneticist will decode your DNA to provide you with the most analytical breakdown possible. Your DNA has all the answers, let MelixGX™ tell you what they are saying. Visit melixgx.com to learn more, and follow us on Facebook and Instagram: https://www.facebook.com/dnatestingkit/ https://www.instagram.com/melixgx/

Xpan is Developing the Next Generation of Minimally Invasive Surgical Access Ports

YouScript is on a mission to eliminate avoidable adverse drug events. Our technology synthesizes evidence impacting drug response, including pharmacogenetic testing, to support doctors and pharmacists in making faster, more proactive decisions at the point of care. We're the only clinically validated system that shows improved outcomes, reduced costs, and high patient and provider satisfaction. We're also successfully integrated into the clinical workflow of Epic, Cerner, Allscripts, PDX, and Telus Health. Equally important is that our team has a combined 100+ years of experience in pharmacogenetics, healthcare, technology development, and disruptive businesses. In pursuit of our mission, we aim to be a trusted partner to value-based healthcare organizations, providers, and payers who want to bend the healthcare cost curve with the power of precision medicine. If you are looking to be a part of the solution to solving one of the many challenges providers and patients face today, we'd love to hear from you. Whether you are a provider looking for a new clinical decision-making support tool or a potential employee looking for a new home, we can't wait to share more about what's happening at YouScript!

Zephyr AI uses large complex data and proprietary algorithms to discover new insights and opportunities for Personalized/Precision Medicine, Drug Discovery, Drug Rescue, and Clinical Decision Support. Zephyr AI partners with leading health systems, health insurance plans, and biotechnology pioneers to improve Quality, Outcomes and Costs.